Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 1, 2001, Pages 93-96

  Dhople, A M ^a  

^a Florida Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMIDOPRIM; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; EPIROPRIM; K 130; PYRIMIDINE DERIVATIVE; SULFONE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; PREVALENCE;

EID: 0035187886     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.1.93     Document Type: Article

References (10)

1. New mycobacterial infection in man: Clinical aspects
2. Heat treatment of Mycobacterium ulcerans infections without surgical excision
3. DDS sensitivity of mycobacteria. Antagonistic effect of PABA for M. ulcerans and M. kansasii
4. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae
5. Combinations of rifampin or rifabutin plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects
6. New analogs of trimethoprim
7. Effect of brodimoprim on Mycobacterium leprae in vitro and in mouse foot-pads
8. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae
9. Epidemiology of disease caused by nontuberculous mycobacteria